Loading...
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice
There is a critical need for alternative, potent agents that can reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with heterozygous familial hyperlipidemia and statin intolerance and those not reaching lipid-lowering treatment goals who are at high risk for cardiovascular (CV) e...
Na minha lista:
| Udgivet i: | Am Health Drug Benefits |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Engage Healthcare Communications, LLC
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4719137/ https://ncbi.nlm.nih.gov/pubmed/26834934 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|